Compounds have potential for Alzheimer's treatment, study suggests
21 Aug 2008

A select group of microtubule-associated proteins which interact with a protein in the brain could be used in the diagnosis and treatment of Alzheimer's disease and other dementia-related conditions, new research suggests.

Staff from the Centre for Molecular Neurobiology at Ohio State University have found that these compounds interact in three specific ways with the tau protein, which - in a healthy brain - binds to and stabilises structures within the organ that are needed for normal functioning.

Tau protein which break away from such structures can form strands called filaments, which, when tangled, are a sign of Alzheimer's and other neurodegenerative diseases.

Scientists are observing three possible outcomes of tau protein breaking away - binding to protein filaments, inhibit such filaments from developing or drive tau proteins to form filaments.

"It's important now to find compounds that can be used in imaging because the earlier clinicians can detect the disease, the better the chances are that a drug will halt disease progression while patients still have strong cognitive abilities," comments postdoctoral researcher Nicolette Honson.

Any clinical use of the compounds will require years of additional research, as the interactions have been observed in test tubes and cell cultures.

Login and visit the Alzheimer's Disease Knowledge Centre

Print Article    Bookmark

• Blood sugar warning for the prevention of Alzheimer's 30/12/08
• Brain starvation seems to trigger Alzheimer's, study suggests 29/12/08
• Plans for new Alzheimer's clinics unveiled 24/12/08
• Cardiovascular proteins found to work together to speed up Alzheimer's 22/12/08
• Research looks at strategy games in the prevention of cognitive deterioration 12/12/08

• EBIXA 10mg film-coated tablets - 50.88%
  Treatment of patients with moderately severe to severe Alzheimers disease ...
  
  
• CERETEC - 26.56%
  ... the diagnosis of abnormalities of regional cerebral blood flow, such as those occurring following stroke and other cerebrovascular disease, epilepsy, Alzheimer's Disease and other forms of dementia, transient ischaemic attack, migraine and tumours of the brain. (ii) Technetium [99mTc] Exametazime ...
  
  
• EBIXA 10 mg/g oral drops, solution - 25.26%
  Treatment of patients with moderate to severe Alzheimer's disease ...
  
  
• EXELON Capsules - 25.26%
  Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease ...
  
  
• CEREZYME 400 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...
  
  
• CEREZYME 200 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...